{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:09:18Z","timestamp":1776348558357,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T00:00:00Z","timestamp":1422835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000277","name":"Department for Food, Environment and Rural Affairs, UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000277","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Spanish Ministerio de Economia y Competitividad"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.antiviral.2015.01.009","type":"journal-article","created":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T08:10:17Z","timestamp":1422605417000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge"],"prefix":"10.1016","volume":"116","author":[{"given":"Eva","family":"Calvo-Pinilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"de la Poza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Gubbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Paul Clement","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ortego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Castillo-Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.antiviral.2015.01.009_b0005","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"issue":"Pt 4","key":"10.1016\/j.antiviral.2015.01.009_b0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1099\/0022-1317-81-4-993","article-title":"Identification of antigenic regions on VP2 of African horse sickness virus serotype 3 by using phage-displayed epitope libraries","volume":"81","author":"Bentley","year":"2000","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.009_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2015.01.009_b0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02239981","article-title":"Observations on antibody levels associated with active and passive immunity to African horse sickness","volume":"20","author":"Blackburn","year":"1988","journal-title":"Trop. Anim. Health Prod."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.009_b0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1006\/viro.1993.1537","article-title":"Neutralizing epitopes of African horse sickness virus serotype 4 are located on VP2","volume":"196","author":"Burrage","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.01.009_b0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.009_b0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.vaccine.2009.10.027","article-title":"Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(\u2212\/\u2212) mice against lethal bluetongue infection","volume":"28","author":"Calvo-Pinilla","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.009_b0040","doi-asserted-by":"crossref","first-page":"e16503","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR \u2212\/\u2212 mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.009_b0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0264-410X(03)00538-3","article-title":"Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals","volume":"22","author":"Cosma","year":"2003","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.antiviral.2015.01.009_b0050","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/evj.12015","article-title":"Passive transfer and rate of decay of maternal antibody against African horse sickness virus in South African thoroughbred foals","volume":"45","author":"Crafford","year":"2013","journal-title":"Equine Vet. J."},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.009_b0055","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4049\/jimmunol.175.1.591","article-title":"Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals","volume":"175","author":"Chen","year":"2005","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.antiviral.2015.01.009_b0060","doi-asserted-by":"crossref","first-page":"e5997","DOI":"10.1371\/journal.pone.0005997","article-title":"Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA)","volume":"4","author":"Chiam","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.01.009_b0065","doi-asserted-by":"crossref","first-page":"e70197","DOI":"10.1371\/journal.pone.0070197","article-title":"Ns1 is a key protein in the vaccine composition to protect Ifnar(-\/-) mice against infection with multiple serotypes of African horse sickness virus","volume":"8","author":"de la Poza","year":"2013","journal-title":"PloS one"},{"issue":"39","key":"10.1016\/j.antiviral.2015.01.009_b0070","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2013.05.091","article-title":"Utilizing poxviral vectored vaccines for antibody induction-progress and prospects","volume":"31","author":"Draper","year":"2013","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2015.01.009_b0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"El Garch","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"6","key":"10.1016\/j.antiviral.2015.01.009_b0080","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/JVI.03418-13","article-title":"A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection","volume":"88","author":"Garcia-Arriaza","year":"2014","journal-title":"J. Virol."},{"issue":"39","key":"10.1016\/j.antiviral.2015.01.009_b0085","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.01.009_b0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/156652308784049363","article-title":"The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer","volume":"8","author":"Gomez","year":"2008","journal-title":"Curr. Gene Ther."},{"issue":"4","key":"10.1016\/j.antiviral.2015.01.009_b0095","doi-asserted-by":"crossref","first-page":"e60574","DOI":"10.1371\/journal.pone.0060574","article-title":"Protection of IFNAR (\u2212\/\u2212) mice against bluetongue virus serotype 8, by heterologous (DNA\/rMVA) and homologous (rMVA\/rMVA) vaccination, expressing outer-capsid protein VP2","volume":"8","author":"Jabbar","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.antiviral.2015.01.009_b0100","first-page":"403","article-title":"A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques","volume":"52","author":"Jeggo","year":"1984","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.009_b0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0034-5288(18)32007-1","article-title":"Role of neutralising antibody in passive immunity to bluetongue infection","volume":"36","author":"Jeggo","year":"1984","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.antiviral.2015.01.009_b0110","first-page":"480","article-title":"50% end-point calculation","volume":"162","author":"Karber","year":"1931","journal-title":"Arch. Exp. Pathol. Pharmak."},{"issue":"11","key":"10.1016\/j.antiviral.2015.01.009_b0115","doi-asserted-by":"crossref","first-page":"e7790","DOI":"10.1371\/journal.pone.0007790","article-title":"MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A\/H5N1 viruses at low doses and after single immunization","volume":"4","author":"Kreijtz","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.009_b0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/viro.1995.1355","article-title":"Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus","volume":"210","author":"Martinez-Torrecuadrada","year":"1995","journal-title":"Virology"},{"issue":"Pt 6","key":"10.1016\/j.antiviral.2015.01.009_b0125","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1099\/0022-1317-77-6-1211","article-title":"Full protection against African horse sickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7","volume":"77","author":"Martinez-Torrecuadrada","year":"1996","journal-title":"J. Gen. Virol."},{"issue":"Pt 10","key":"10.1016\/j.antiviral.2015.01.009_b0130","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1099\/0022-1317-82-10-2415","article-title":"Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides","volume":"82","author":"Martinez-Torrecuadrada","year":"2001","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2015.01.009_b0135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1051\/vetres:2004021","article-title":"African horse sickness","volume":"35","author":"Mellor","year":"2004","journal-title":"Vet. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2015.01.009_b0140","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","article-title":"Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults","volume":"8","author":"Ogwang","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.009_b0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.vetimm.2012.01.016","article-title":"Virus-specific CD8(+) T-cells detected in PBMC from horses vaccinated against African horse sickness virus","volume":"146","author":"Pretorius","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"16","key":"10.1016\/j.antiviral.2015.01.009_b0150","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1128\/JVI.74.16.7651-7655.2000","article-title":"Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector","volume":"74","author":"Ramirez","year":"2000","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.009_b0155","first-page":"139","article-title":"Immune responses in a horse inoculated with the VP2 gene of African horse sickness virus","volume":"66","author":"Romito","year":"1999","journal-title":"Onderstepoort J. Vet. Res."},{"issue":"3\u20134","key":"10.1016\/j.antiviral.2015.01.009_b0160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0147-9571(94)90046-9","article-title":"African horse sickness virus structure","volume":"17","author":"Roy","year":"1994","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.01.009_b0165","first-page":"177","article-title":"New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles","volume":"14","author":"Roy","year":"1998","journal-title":"Arch. Virol. Suppl."},{"issue":"7\u20138","key":"10.1016\/j.antiviral.2015.01.009_b0170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(01)00445-5","article-title":"The protective efficacy of a recombinant VP2-based African horse sickness subunit vaccine candidate is determined by adjuvant","volume":"20","author":"Scanlen","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.009_b0175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/viro.1996.0304","article-title":"Immunization with VP2 is sufficient for protection against lethal challenge with African horse sickness virus Type 4","volume":"220","author":"Stone-Marschat","year":"1996","journal-title":"Virology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T09:55:17Z","timestamp":1566294917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":35,"alternative-id":["S0166354215000108"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}